Microdialysis Study of Aztreonam-Avibactam Distribution in Peritoneal Fluid and Muscle of Rats with or without Experimental Peritonitis

Antimicrobial Agents and Chemotherapy
Alexia ChauzySandrine Marchand

Abstract

The purpose of this study was to investigate aztreonam (ATM) and avibactam (AVI) distribution in intraperitoneal fluid and muscle interstitial fluid by microdialysis in rats, with or without peritonitis, and to compare the unbound concentrations in tissue with the unbound concentrations in blood. Microdialysis probes were inserted into the jugular veins, hind leg muscles, and peritoneal cavities of control rats (n = 5) and rats with intra-abdominal sepsis (n = 9) induced by cecal ligation and punctures. ATM and AVI probe recoveries in each medium were determined for both molecules in each rat by retrodialysis by drug. ATM-AVI combination was administered as an intravenous bolus at a dose of 100-25 mg · kg-1 Microdialysis samples were collected over 120 min, and ATM-AVI concentrations were determined by liquid chromatography-tandem mass spectrometry. Noncompartmental pharmacokinetic analysis was conducted and nonparametric tests were used for statistical comparisons between groups (infected versus control) and medium. ATM and AVI distribution in intraperitoneal fluid and muscle was rapid and complete both in control rats and in rats with peritonitis, and the concentration profiles in blood, intraperitoneal fluid, and muscle were...Continue Reading

References

Jul 1, 1993·Pharmaceutical Research·B Davies, T Morris
Jan 6, 1999·Critical Care Medicine·G FriedmanJ L Vincent
Mar 3, 1999·The Journal of Antimicrobial Chemotherapy·T Dalla CostaH Derendorf
Dec 8, 2000·Advanced Drug Delivery Reviews·A de la PeñaH Derendorf
Dec 8, 2000·Advanced Drug Delivery Reviews·R K Verbeeck
Apr 30, 2002·International Journal of Antimicrobial Agents·Ping LiuHartmut Derendorf
Apr 24, 2004·Antimicrobial Agents and Chemotherapy·Markus MüllerHartmut Derendorf
May 27, 2005·Antimicrobial Agents and Chemotherapy·Sandrine MarchandWilliam Couet
Oct 15, 2005·Nature Reviews. Drug Discovery·Jon A BurasMichail Sitkovsky
Dec 24, 2005·Shock·William J HubbardIrshad H Chaudry
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Sandrine LefeuvreWilliam Couet
Jan 16, 2008·Antimicrobial Agents and Chemotherapy·Sandrine LefeuvreWilliam Couet
Dec 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinJohn G Bartlett
Feb 8, 2011·Trends in Microbiology·Lien DejagerClaude Libert
Jan 9, 2013·World Journal of Emergency Surgery : WJES·Massimo SartelliTomohisa Shoko
Mar 13, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Karthick VishwanathanShampa Das
Jul 15, 2015·Bioanalysis·Henrik SillénKaren Glendining
Apr 24, 2016·The Journal of Antimicrobial Chemotherapy·Sherwin K B SyHartmut Derendorf
Jun 24, 2016·The Journal of Antimicrobial Chemotherapy·Christopher Ramsey, Alasdair P MacGowan
Feb 1, 2018·The Journal of Antimicrobial Chemotherapy·T W FeltonK A Rodvold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

© 2022 Meta ULC. All rights reserved